Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 629-780-6 | CAS number: 1234694-02-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study, however with following deficiencies: hematology and clinical chemistry examinations were only conducted for males and no neurobehavioural examinations were done.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 000
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted in 1996
- Deviations:
- yes
- Remarks:
- no neurobehavioural examination performed; hematology and clinical chemistry only was done on males.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Methyl laurate
- EC Number:
- 203-911-3
- EC Name:
- Methyl laurate
- Cas Number:
- 111-82-0
- Molecular formula:
- C13H26O2
- IUPAC Name:
- methyl laurate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Strain as given in study report: Sprague-Dawley; Crj:CD(SD)
- Source: Charles River Laboratories Japan, Inc., Atsugi, Japan
- Age at study initiation: 10 weeks
- Weight at study initiation: 354 - 386 g (males), 216 - 241 g (females)
- Housing: stainless steel cage
- Diet: NMF from Oriental Yeast Co., Ltd
- Water: tap water
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 ± 2
- Humidity (%): 55 ± 10
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12 (light intensity 150 - 300 lux)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was dissolved in corn oil. Dosing solutions were prepared once or more a week, kept under seal, cool and dark until use and used within 7 days after preparation. 5 % (w/v) was confirmed to be stable for at least 8 days under cool and dark condition. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of the concentration was conducted using a sample by random-choice from each batch. Since 98.6 - 104 % was shown as a result, it was confirmed that given amount of test item was included.
- Duration of treatment / exposure:
- females: 14 days before mating until day 3 of lactation (41 - 55 days)
males: 45 days - Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
250, 500 and 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - The animals were mated.
- Terminal sacrifice was on day 45 for males and on day 4 of lactation for females.
- Dose selection rationale: A preliminary test was performed to determine the dose range for the main test. Groups of male and female animals received 0, 250, 500, 750 and 1000 mg/kg bw/day of the test item for 14 consecutive days. No mortality was observed and the general health state was not affected by treatment; no changes in weight, food consumption, gross pathology, organ weights, blood chemistry and hematology were noticed.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: Males on days 1, 8, 15, 22, 29, 36 and 43 of administration; Females on days 1, 8 and 15 before mating, on days 0, 7, 14 and 21 of gestation and on days 0 and 4 of lactation.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: yes
- Time schedule: days 1-8, 8-15, 22-29, 29-36, 36-43 and 43-45 in male animals; days 1-8, 8-15 before mating, days 0-7, 7-14 and 14-21 of gestation and during days 0-4 of lactation in females.
FOOD EFFICIENCY: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At necropsy
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes (16 hours)
- How many animals: 12 males per dose
- Parameters checked: Hematocrit (Hct), Hemoglobin (Hgb), Red Blood Cell Count (RBC), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), Platelet Count (PLT), White Blood Cell Count (WBC), Differential leukocyte counts.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At necropsy
- How many animals: 12 males per dose
- Parameters checked: Total protein, albumin, A/G, glucose, Blood Urea Nitrogen (BUN), creatinine, total cholesterol, Glutamate Oxaloacetate Transaminase (GOT), Glutamate–Pyruvate Transaminase (GPT), gamma-GTP, total bilirubin, potassium, chloride, calcium, inorganic phosphorus
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes, absolute and relative weights
- How many animals: 10- 12 animals per dose
- Organs: thymus, liver, kidneys, testes, epididymides, ovaries, lung.
GROSS PATHOLOGY: Yes
Males: thymus, lungs, liver, kidney, brain, heart, spleen, adrenal gland, seminal vesicles, prostate, testis and epididymides.
Females in control and highest dose group at day 4 of lactation: thymus, lung, liver, kidney, ovary, heart, spleen, adrenal, colon.
Non-pregnant females: skin, breast, lymph nodes, salivary glands, sternum, femur (including marrow), thymus, trachea, bronchi and lungs, heart, thyroid and parathyroid glands, tongue, esophagus, stomach, duodenum, small intestine, colon, liver, pancreas, spleen, kidney, adrenal gland, bladder, ovaries, uterus, vagina, eye, Harderian gland, brain, pituitary, spinal cord.
Females with all dead pups: skin, breast, lymph nodes, salivary glands, sternum, femur (including marrow), thymus, trachea, bronchi, lungs, heart, thyroid and parathyroid glands, tongue, esophagus, stomach, duodenum, small intestine, colon, liver, pancreas, spleen, kidney, adrenal gland, bladder, ovaries, uterus, vagina, eye, Harderian gland, brain, pituitary and spinal cord.
Newborns: major organs.
HISTOPATHOLOGY: Yes
Males in control and highest dose group with proven fertility: brain, thymus, heart, lungs, liver, kidney, spleen, testis and adrenal gland.
Females in control and highest dose group at day 4 of lactation: brain, thymus, heart, lungs, liver, kidney, spleen, adrenal and ovaries
Non-pregnant females and infertile males: brain, thymus, heart, lungs, liver, kidney, spleen, adrenal glands, vagina, uterus, ovaries, testis, epididymides, seminal vesicles, prostate and pituitary gland.
Females with all dead pups: skin, breast, lymph nodes, salivary glands, sternum, femur (including marrow), thymus, trachea, bronchi and lungs, heart, thyroid and parathyroid glands, tongue, esophagus, stomach, duodenum, small intestine, large intestine, liver, pancreas, spleen, kidney, adrenal gland, bladder, ovaries, uterus, vagina, eye, Harderian gland, brain, spinal cord and pituitary gland. - Other examinations:
- Estrus cycle, reproductive performance, observation of pups
- Statistics:
- Barlett test, One-way ANOVA, Kruskal-Wallis test, Dunnett test, Scheffe test, Chi-square test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Mortality was not observed in either group throughout the treatment period for both sexes.
Fracture of incisors was seen in one control male (day 5 to 7), and in the 250 mg/kg bw/day group, two males showed alopecia and crusting; the findings were regarded as not treatment-related. The females were inconspicuous.
BODY WEIGHT AND WEIGHT GAIN
Difference between treatment groups and the control group throughout the treatment period was not observed in both sexes.
FOOD CONSUMPTION
In males, higher mean food consumption was observed in the 250 and 500 mg/kg bw/day groups compared with control; however, the finding was not considered to be a relevant effect. In females, no difference in food consumption between treated and and control animals was noticed.
HAEMATOLOGY
No difference between treatment groups and control group was found.
CLINICAL CHEMISTRY
No difference between treatment groups and control group was found.
ORGAN WEIGHTS
In males of the 1000 mg/kg bw/day group, actual weight of the thymus was increased compared to control. But this change was regarded as non-relevant since no difference was observed in female groups.
GROSS PATHOLOGY
In fertile males, few cases of colored spots / areas in lung were reported (control and treated animals) ; the findings were nor related to treatment. Also red spots / areas in the thymus were reported for 2 males of the 500 mg/kg bw/day group, and gray spots / areas of the skin wereobserved in one male of the 250 mg/kg bw/day group.
In naturally delivering females and in each group including control, thymus atrophy, colored spots / area in the lungs, atrophy of the large intestine, white spots / areas in the liver, cysts of the ovary and scarring of the kidney were reported; all these changes were without toxicological relevance. Two animals in 250 mg/kg bw/day group were not successfully pregnant but showed no abnormal findings. The two animals, whose all pups died before day 4 of lactation, were control animals and one of them showed redness of the eye.
HISTOPATHOLOGY: NON-NEOPLASTIC
In the fertile males, granuloma of the liver lesion, basophilic tubules of the kidney, acidophilic bodies appearance in the kidney and vacuolated adrenal glands were observed. No abnormality was observed in thymus in the 1000 mg/kg bw/day group, where increase of organ weights was observed. In females having delivered naturally, pigmented spleen, aggregated macrophages in the lungs, focal granulomas in the liver, basophilic tubules and vacuolation of the kidney were observed in each group. In the two females of the control group with pups having died before day 4 of lactation, mammary gland hyperplasia, accumulations of macrophages, blood vessel expansion arteritis of the uterus were observed. An infertile male in 250 mg/kg bw/day group showed sperm granulomas of the epididymides.
However, all these changes were considered to be not toxicologically relevant, since there were no difference of the number of occurrence between each group.
OTHER FINDINGS:
Parent animal reproduction:
Reproductive performance displayed no significant differences between treatment groups and controls (estrous cycle, copulation index, fertility index, gestation length, gestation index, delivery conditions, or implantation index). In control and in the 1000 mg/kg bw/day group, since there was bias in the number of male and female infants, sex ratio was significantly different between these groups. Since many pups died before day four of lactation in the control group, number of total live female pups was significantly different between the control and 1000 mg/kg bw/day group. But no difference was found in delivery, pregnant duration, number of corpora lutea, number of implantation scars, and fetal birth of live or dead pups, birth rate, implantation rate, delivery percentage and fertility rate.
Pups:
2 case of hypodermic hemorrhage, 1 case of imperforated anus and 1 case of rudiment tail were observed in control group, 1 case of nanooffspring was seen in the 250 mg/kg bw/day group, 1 case of short tail was observed in the 500 mg/kg bw/day group. Regarding weight, no difference was observed. At necropsy, thymic remnant in the neck was observed in control and in the 250 and 1000 mg/kg bw/day group, diaphragmatic hernia was observed in two dead pups in the 500 mg/kg bw/day group.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects (clinical signs; mortality; body weight; food consumption; hematology; clinical chemistry; gross pathology; organ weights; histopathology) observed in all dose groups
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.